Plain-English translation of NCT07025369 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a hormone-lowering medication, can help improve the clarity of special cancer-detecting imaging scans (called PSMA PET/CT scans) in men with high-risk or very high-risk prostate cancer. The study will compare how well the medication helps doctors spot cancer before and after treatment. Your participation would involve taking the medication for 5, 10, or 15 days, having two imaging scans, and then undergoing surgery to remove your prostate.
Current imaging scans don't always catch all signs of prostate cancer, which can affect treatment decisions. Researchers believe that this medication might temporarily change cancer cells in a way that makes them show up better on these special imaging scans, helping doctors see the full extent of the disease.
You likely qualify if…
You likely don't qualify if…
You will start with an imaging scan on day one. Then you'll take the study medication once daily for either 5, 10, or 15 days (depending on which group you're randomly assigned to). On your final day of medication, you'll have a second imaging scan to see if the medication improved how well the cancer shows up. Within 3 months, you'll have surgery to remove your prostate and nearby lymph nodes. Throughout the study, you'll have blood samples taken to monitor your health and hormone levels.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States